Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM. Kandel, Isabelle Borget, Philippe Saïag et al.|European Journal of Cancer|2018Cited by 38
Quality‐of‐life assessment in French patients with metastatic melanoma in real lifeM. Kandel, Isabelle Borget, Stéphane Dalle et al.|Cancer|2019Cited by 14
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceM. Kandel, Isabelle Borget, A. Bardet et al.|Current Oncology|2022Cited by 5
Données actualisées d’efficacité et de tolérance de l’ipilimumab en « vie réelle » via la cohorte MelbaseClara Allayous, Célèste Lebbé, Raphaël Porcher et al.|Annales de Dermatologie et de Vénéréologie|2016Cited by 1